Terms: = Lung cancer AND UBR5, EDD, 51366, ENSG00000104517, EDD1, KIAA0896, HYD, MGC57263, DD5, O95071, FLJ11310 AND Treatment
6 results:
1. The Ethanolic Extract of
Park HJ; Park SH
Nutr Cancer; 2024; 76(3):305-315. PubMed ID: 38185896
[No Abstract] [Full Text] [Related]
2. Independent calculation-based verification of volumetric-modulated arc therapy-stereotactic body radiotherapy plans for lung cancer.
Ono T; Mitsuyoshi T; Shintani T; Tsuruta Y; Iramina H; Hirashima H; Miyabe Y; Nakamura M; Matsuo Y; Mizowaki T
J Appl Clin Med Phys; 2020 Jul; 21(7):135-143. PubMed ID: 32391645
[TBL] [Abstract] [Full Text] [Related]
3. lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers.
Cao C; Wang Q; Liu Y
Drug Des Devel Ther; 2019; 13():1087-1098. PubMed ID: 31118562
[No Abstract] [Full Text] [Related]
4. Pediatric lung adenocarcinoma presenting with brain metastasis: a case report.
De Martino L; Errico ME; Ruotolo S; Cascone D; Chiaravalli S; Collini P; Ferrari A; Muto P; Cinalli G; Quaglietta L
J Med Case Rep; 2018 Sep; 12(1):243. PubMed ID: 30172261
[TBL] [Abstract] [Full Text] [Related]
5. E3 Ubiquitin Ligase ubr5 Drives the Growth and Metastasis of Triple-Negative Breast cancer.
Liao L; Song M; Li X; Tang L; Zhang T; Zhang L; Pan Y; Chouchane L; Ma X
Cancer Res; 2017 Apr; 77(8):2090-2101. PubMed ID: 28330927
[TBL] [Abstract] [Full Text] [Related]
6. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.
Metro G; Chiari R; Baldi A; De Angelis V; Minotti V; Crinò L
Future Oncol; 2013 Feb; 9(2):167-77. PubMed ID: 23414467
[TBL] [Abstract] [Full Text] [Related]
